Sign in Subscribe

Romain Dorange

The race to biomarkers — but are we measuring the right ones?

The race to biomarkers — but are we measuring the right ones?

More is not always better. A look at what the at-home testing market is actually selling, what it's missing, and what a rational panel should look like. This is the third piece in the Late Night Convo series. The first was about how we rebuilt Biostarks as

Reading the at-home biomarker M&A wave

Reading the at-home biomarker M&A wave

Seven moves in seven months, and what they tell us about layers, lock-in, and the limits of building on Quest. This is the second piece in the Late Night Convo series. The first one was about us — how we are rebuilding Biostarks as an AI-native at-home biomarker

Making Biostarks an AI native at-home biomarker testing company

Making Biostarks an AI native at-home biomarker testing company

This is the first in a series of articles on how we are designing and operating Biostarks in the age of AI. Not a manifesto — a working account of what we are actually building. When we completed the acquisition of Biostarks in summer 2025, AI for the organisation meant mostly

Hello, World.

Hello, World.

This is Thought Leadership on Building Biostarks. Things will be up and running here shortly, but you can subscribe in the meantime if you'd like to stay up to date and receive emails when new content is published!